Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Industry: Biotechnology

Sector: Healthcare

Phone: 416-477-1708

Website: psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada

RuddyRolls Sep. 14 at 1:32 AM

$PBM "The big one is ibogaine".

0 · Reply

MingChoo Sep. 13 at 12:43 PM

$PBM Looking good8

0 · Reply

et1000 Sep. 11 at 11:30 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $SIG $EVI $PBM $MSS mobing

0 · Reply

topstockalerts Sep. 11 at 10:17 PM

$PBM a lot to like about this action

0 · Reply

LongBallBarn Sep. 11 at 5:03 PM

$UPC $PBM

0 · Reply

prismmarketview Sep. 11 at 4:11 PM

PRISM Mid-Day Movers: Crypto Mining and Cybersecurity are Today’s Leaders. Canaan Inc. (NASDAQ: $CAN ) shares were up 13.74%Friday, gaining $0.0424 to trade at $0.3511. authID Inc. (NASDAQ: $AUID ) shares climbed 10.31% Friday to $0.3958, a gain of $0.037 from the prior close of $0.3588. Other Notable Movers: Psyence Biomed ($PBM ) up 10% Babcock & Wilcox ($BW ) up 9% CPI Card Group ($PMTS )down -15% Stock prices and percentage changes are as of 12:00 p.m. ET on September 11, 2026, and are subject to change. https://prismmarketview.com/prism-mid-day-movers-crypto-mining-and-cybersecurity-are-todays-leaders/

0 · Reply

barrymcockinner1 Sep. 11 at 3:55 PM

$PBM 😋😋😋

0 · Reply

Jbjb90 Sep. 11 at 3:48 PM

$PBM lets fucking go, back up closer to where we belong. Any big news this pops above 10 easily 💪

0 · Reply

RuddyRolls Sep. 11 at 3:38 PM

$PBM https://x.com/SecKennedy/status/2098110266533659119 https://youtu.be/eOyE2dFLuNQ?si=rFpzop-WfIWLOiJO

0 · Reply

SonOfSea Sep. 11 at 3:35 PM

$PBM is it breakout?

0 · Reply

Psyence Biomedical files to sell 1.15M common shares for holders

Aug 18, 2026, 5:23 PM EDT - 26 days ago

Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development

Jun 16, 2026, 10:00 AM EDT - 2 months ago

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

2026-05-15T14:51:49.000Z - 4 months ago

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

May 15, 2026, 9:15 AM EDT - 4 months ago

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Apr 23, 2026, 7:00 AM EDT - 4 months ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

2026-04-20T12:19:33.000Z - 4 months ago

Psyence Biomedical provides update on position in global ibogaine market

Apr 20, 2026, 7:42 AM EDT - 4 months ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

2026-04-18T00:33:00.000Z - 4 months ago

Why Is Psyence Biomedical Stock (PBM) Up Today?

2026-04-17T19:16:22.000Z - 4 months ago

Psyence Biomedical Ltd trading resumes

2026-04-17T19:12:01.000Z - 4 months ago

Psyence Biomedical Ltd trading halted, volatility trading pause

2026-04-17T13:26:00.000Z - 4 months ago

Psyence acknowledges reports on U.S. action to advance Ibogaine research

Apr 17, 2026, 9:15 AM EDT - 4 months ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 8, 2026, 9:15 AM EDT - 5 months ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Mar 11, 2026, 9:15 AM EDT - 6 months ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

2026-03-03T14:22:48.000Z - 6 months ago

Psyence Biomedical announces export of psilocybin to Australia

Mar 3, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Feb 20, 2026, 5:20 PM EST - 6 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

2026-02-17T14:27:42.000Z - 6 months ago

Psyence Biomedical announces results of annual, special meeting

Feb 17, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 13, 2026, 6:30 PM EST - 7 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

2026-02-11T14:20:57.000Z - 7 months ago

Psyence Biomedical announces settlement of shareholder litigation

Feb 11, 2026, 9:15 AM EST - 7 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Jan 28, 2026, 6:30 PM EST - 7 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 22, 2026, 1:42 PM EST - 7 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 20, 2026, 7:19 AM EST - 7 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 12, 2026, 8:30 AM EST - 8 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 5, 2026, 9:15 AM EST - 8 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Dec 19, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 10 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

RuddyRolls Sep. 14 at 1:32 AM

$PBM "The big one is ibogaine".

0 · Reply

MingChoo Sep. 13 at 12:43 PM

$PBM Looking good8

0 · Reply

et1000 Sep. 11 at 11:30 PM

0 · Reply

topstockalerts Sep. 11 at 10:17 PM

$PBM a lot to like about this action

0 · Reply

LongBallBarn Sep. 11 at 5:03 PM

$UPC $PBM

0 · Reply

prismmarketview Sep. 11 at 4:11 PM

0 · Reply

barrymcockinner1 Sep. 11 at 3:55 PM

$PBM 😋😋😋

0 · Reply

Jbjb90 Sep. 11 at 3:48 PM

$PBM lets fucking go, back up closer to where we belong. Any big news this pops above 10 easily 💪

0 · Reply

RuddyRolls Sep. 11 at 3:38 PM

$PBM https://x.com/SecKennedy/status/2098110266533659119 https://youtu.be/eOyE2dFLuNQ?si=rFpzop-WfIWLOiJO

0 · Reply

SonOfSea Sep. 11 at 3:35 PM

$PBM is it breakout?

0 · Reply

RuddyRolls Sep. 11 at 3:35 PM

$PBM "The secretary was speaking on the latest episode of a podcast he hosts for HHS in which he interviewed Bryan Hubbard, the CEO of Americans for Ibogaine. The secretary admitted that he himself is surprised to hear stories of people taking ibogaine once and changing their lives without having to use it again." https://x.com/MarijuanaMoment/status/2098406705402913156

0 · Reply

Jbjb90 Sep. 10 at 6:10 PM

$PBM nice to be back above 5 again

0 · Reply

Tradetime3472 Sep. 10 at 3:57 PM

$PBM $5 EOD 👀

0 · Reply

Ge8888 Sep. 10 at 11:11 AM

$PBM Very bullish target $ 12

2 · Reply

RuddyRolls Sep. 8 at 10:58 PM

$PBM Nobody is shorting this. Just 14k short shares, down from 37k July 31 142k Feb 27 312k Dec 15 When shorts won't touch early stage biotech you know it's a remarkably golden ticket. 🚀 https://themarketmonitors.com/stocks/NASDAQ/PBM/short-interest/

0 · Reply

RuddyRolls Sep. 8 at 8:47 PM

$PBM float is 2.56m shares. Only 60k shares traded moves it 10-15 per cent at times. Which is why with just one piece of decent news (coming in to CMPS approval timeline endless sector news) it can rocket 2-5x. Meanwhile Phase 2b pending and the ibogaine supply business development is all guns blazing in the US as frequent new Ibogaine research contracts get awarded.

0 · Reply

StockSparker Sep. 8 at 8:14 PM

$PBM Getting spicy after hours. Up 20% already from entry. It's still only the beginning 👀🔥

1 · Reply

Jbjb90 Sep. 8 at 2:10 PM

$PBM

0 · Reply

Tradetime3472 Sep. 8 at 1:35 PM

$PBM set up here looks real nice, a nice PR would take it to double digits IMO

0 · Reply

Surferboysa Sep. 8 at 12:29 PM

$PBM time to shine 🙌🙌

0 · Reply

RuddyRolls Sep. 7 at 5:05 AM

$PBM Ibogaine trial featured in The Microdose enews this week: "Arizona embark on one of the first ibogaine clinical trials Researchers from Arizona State University and Phoenix’s Barrow Neurological Institute are examining the safety and efficacy of ibogaine in treating traumatic brain injury after receiving a $5 million grant from the state Department of Health Services. ... Researchers plan to begin enrolling participants for the trial in 2027. The goal is to recruit 40 people with chronic symptoms resulting from brain injury. " https://themicrodose.substack.com/p/a-federal-report-encourages-states

0 · Reply

Market Cap	12.38M
Revenue (ttm)	0.00
Net Income (ttm)	-6.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	134,400
Avg Vol	87,684
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	85%
Beta	1.72
Analysts	Strong Buy
Price Target	N/A